Midbrain organoids for modeling and research in Parkinson's disease
CompanyOrgano Therapeutics, Esch-sur-Alzette, Luxembourg
The company Organo Therapeutics has specialized in the development of brain organoids for research into Parkinson's disease. The models recapitulate important functional and structural properties and express relevant midbrain markers (LMX1 and FOXA2). Organoids derived from tissue samples from healthy donors show a high number of neurons (dopaminergic, glutamatergic, GABAergic) and astrocytes. Organoids obtained from samples from Parkinson's patients show an impairment in neuronal dopamine production following the clinical picture. The company uses various AI-based screening methods to analyse and evaluate the cellular processes. The midbrain organoids have been shown to be useful in modelling Parkinson's and may help advance understanding of pathological processes and improve drug development.
Human midbrain organoids
jens.schwamborn@organo-therapeutics.com
Added on: 08-22-2023
[1] http://organo-therapeutics.com/our-approach-compounds/
